50% OFF Qi Coils - Limited Time Only

Imperial Ginseng Vitality Elixir
Imperial Ginseng Vitality Elixir
Imperial Ginseng Vitality Elixir
Imperial Ginseng Vitality Elixir
Imperial Ginseng Vitality Elixir
Imperial Ginseng Vitality Elixir

Imperial Ginseng Vitality Elixir

Regular price
$59.95
Sale price
$39.95

1000-YEAR-OLD CHINESE FORMULA ORIGINALLY RESERVED FOR ROYALTY

Imperial Ginseng Vitality Elixir is an Ancient, All-Natural Formula, Originally reserved for Royalty to enhance Qi Energy, Mental Focus, Physical Stamina & Vitality. This product is prepared using modern technology in light of ancient prescription and traditional process. We use a patented extraction process which maintains the active ingredient's potency.

Product Details:

  • Quantity: 100 ml
  • 1 bottle provides 20 servings
  • Dosage: 2 Teaspoons, 2-3 Times Per Day (Adult)
  • 100% Natural Ingredients, Non-GMO, Kosher, Halal, Vegan
  • 3 Years Shelf Life
  • Made in Canada

 

Get Quantity Discounts!

3 BOTTLES
Save $20
1 Week Supply
6 BOTTLES
Save $50
2 Weeks Supply
12 BOTTLES
Save $120
1 Month Supply 

 

Ginseng has been used as herbal medicine in ancient China dating back to 100 A.D. In traditional Eastern medicine, it’s believed to it be a source of Chi, the earth’s vital energy that circulates through the body at all times.

Ginseng has a wide range of time-tested benefits. The root is filled with antioxidant properties and has the potential to both increase your energy levels and decrease stress.

General Benefits:

  • Increases vitality & stamina for wellness and longevity
  • Improves mental focus for the most difficult tasks
  • Enhances overall physical activity, especially sports
  • Speeds up physical recovery from fatigue or injuries
  • Improves blood circulation for better health
  • Helps protect the body against physical, mental, and emotional stress by strengthening the immune system
  • Safe for long-term use, and non-habit forming (Use as an alternative to caffeine)
  • It brings balance to your body and helps to normalize all systems
  • Anti-inflammatory
  • Powerful Antioxidant, especially for brain and heart

Medicinal Facts

Each Teaspoon Contains mg Value

Radix Ophiopoginis Extract 5:1
(Ophiopogon Japonicas, Root)
200 mg
CANPHY Asian Ginseng Extract 5:1
(Panax Ginseng, Root)
100 mg
Schisandra Extract 5:1
(Schisandra Chinensis)
100 mg

Non-Medicinal Ingredients: Ethylparaben, Pure Water, Glucose Syrup

 

Directions for Use:

  • Recommended Dosage: adult, take 2 teaspoons, 3 times per day
  • Storage: Keep in a cool, dry place, away from direct sunlight and heat.
  • Keep out of reach of children. Do not use if seal is broken.

 

 

ADD TO CART NOW!

 

Caution and Warnings: If symptoms persist, consult your health care practitioner immediately. If with hypertension or taking prescription medication, consult your health care practitioner prior to use. Use extreme caution in cases of high fever, or where pathogenic influence has not yet to injure, this might prolong the disease. Do not use this product if pregnant, breast-feeding, with diabetes, with chronic cough, with lung deficiency with exterior syndrome. Do not combine with Rhizima and Radix Verati.

Counter Indications: This product has astringent qualities, and is contraindicated in patients with exterior syndrome or Interior heat conditions.

Ginseng

Ginseng is a tonic herb used for rejuvenate and invigorate. It is considered an adaptogen, providing non-specific protection against various mental, physical and environmental forms of stress. Panax ginseng is a slow-maturing perennial herb native to the mountain forests of northeastern China, Korea, and Russia. The plant is cultivated extensively in China, Japan, Korea, Russia, Canada and Wisconsin in the US. Ginseng usually starts flowering at its fourth year and the roots take four to six years to reach maturity. Panax ginseng is one of the most heavily cultivated and widely consumed herbs on earth.

Ginseng root consists of the dried main root, lateral roots and root hairs or “tailings” of P. ginseng C.A. Meyer. According to Germany’s Commission E, ginseng root contains at least 1.5% ginsenosides, calculated as ginsenoside Rg1. Natural unprocessed ginseng root is white in appearance. So-called red ginseng root is prepared from white ginseng by various processing methods, such as steaming the fresh root before drying. Panax ginseng is sold in types and grades, depending on its geographic origin, root maturity, parts of the root used (main root or “tailings”), and methods of preparation or processing such as bleaching or processing into “red” root.

Ginseng's genus name Panax is derived from the Greek, and means panacea or cure-all. In Asian medicine, dried ginseng is used as a tonic to revitalize and replenish vital energy, which is referred to as qi or chi. Ginseng is traditionally used as an aid during convalescence and as a prophylactic to build resistance, reduce susceptibility to illness, and promote health and longevity. In traditional Chinese medicine Panax ginseng is usually prescribed in combination with other herbs as “teapot” medicine. 1,2,3,4

Panax ginseng is listed in the national pharmacopeias of China, Japan, Russia, Austria, France, Germany and Switzerland. It is widely used to treat fatigue, impotence, lack of appetite, headache, dizziness, cancer and rheumatism. The Pharmacopoeia of the People's Republic of China indicates its use for prostration with impending collapse marked by cold limbs and faint pulse; diminished function of the spleen with loss of appetite; diabetes caused by "internal heat"; general weakness with irritability and insomnia in chronic diseases; impotence or frigidity; and heart failure and cardiogenic shock. 2, 7

Phytochemicals and Activities

Ginseng root contains various polysaccharides, saponins, sterols, polyalkenes and essential oil. The biologically active constituents in P. ginseng are triterpene saponins known collectively as ginsenosides. They are also referred to in some literature as “panaxosides.” At least 30 ginsenosides have been identified in Panax ginseng. Of these, ginsenosides Rg1 , Rc, Rd, Rb1 , Rb2 , and Rb0 are generally regarded as the most important. Ginsenoside values of ginseng root vary according to origin, plant maturity and other factors.

Ginseng appears to act as a CNS stimulant, promotes resistance to stress and fatigue, and helps to improve memory. The root and its extracts increase mental and physical work capacity, The biological activities of individual ginsenosides appear to work in opposition to one another. Ginsenoside Rb1 acts as a CNS suppressant, while ginsenoside Rg1 acts as a CNS stimulant. Ginseng's various biological activities are varied and complex, due not only to ginsenosides but to other compounds such as panacene, which demonstrates hypoglycemic activity, at least one compound with insulinomimetic properties, and compounds which demonstrate antioxidant and antifatigue properties in animal studiess. 1,2,3,5,6,7

Ginseng is reported to possess hormone-like and cholesterol-lowering effects, promotes vasodilatation, and act as an anxiolytic and antidepressant. Numerous animal studies have found whole ginseng extracts and purified ginsenosides effective in stimulating learning, memory, and physical capabilities, promoting radioprotection, improving resistance to infection, possessing antioxidant and antifatigue effects, enhancing energy metabolism, and reducing plasma total cholesterol and triglycerides while elevating HDL levels. 6,7

References

1. Bruneton, J. 1995. Pharmacognosy, Phytochemistry, Medicinal Plants. Paris: Lavoisier Publishing.

2. Leung, A.Y. and S. Foster. 1996. Encyclopedia of Common Natural Ingredients Used in Food, Drugs and Cosmetics, 2nd ed. New York: John Wiley & Sons, Inc.

3. Wichtl M, Bisset NG (eds.). Herbal Drugs and Phytopharmaceuticals. Trans from 2nd German ed., (Stuttgart: Medpharm GmbH Scientific Publishers. 1994).

4. Bown, Deni. The Herb Society Of America Encyclopedia of Herbs & Their Uses. (1st ed., (New York: Dorling Kindersley,1995)

5. Dr. Duke’s Phytochemical and Ethnobotanical databases http://www.ars-grin.gov/cgi-bin/duke/farmacy2.pl February 2, 2006.

6. Blumenthal M, Busse W, Goldberg A, Gruenwald J, Hall T, Riggins CW, Rister RS (eds.). The Complete German Commission E Monographs: Therapeutic Guide to Herbal Medicines. S. Klein, R.S. Rister (trans.). 1st ed., (Austin, TX: American Botanical Council. 1998).

7. Blumenthal M, Goldberg A, Brinckmann J (eds). Herbal Medicine: Expanded Commission E Monographs. 1st ed., (Newton, MA: Integrative Medicine Communications. 2000).

Studies

Protective effect of Sheng-Mai Yin, a traditional Chinese preparation, against doxorubicin-induced cardiac toxicity

Background
Sheng-Mai Yin (SMY), a modern Chinese formula based on Traditional Chinese Medicine theory, has been used to treat cardiovascular diseases in Eastern Asia. Our study focuses on the cardioprotection of SMY against doxorubicin (DOX)-induced cardiac toxicity in vivo.

Methods
Rats were injected with DOX (2.5 mg/kg) in six injections over a 2-week period. SMY was administrated intragastrically at the dose of 8.35, 16.7 and 33.4 g/kg, or 16.7 g/kg only twice a day concurrently with DOX for the 2-weeks. A series of assays were performed to detect the effects of SMY on: (i) heart weight index (HWI) and left ventricular mass index (LVMI); (ii) cardiac function; (iii) heart tissue morphology; (iv) the contents of carboxy terminal propeptide of procollagen typeI (PICP), amino terminal propeptide of procollagen type III (PШNP), transforming growth factor-β1 (TGF-β1), B-type natriuretic peptide (BNP), monocyte chemoattractant protein-1 (MCP-1), interferon gamma (INF-γ) and interleukin 6 (IL-6) by ELISA; (v) the mRNA levels of TGF-β1 and toll-like receptor-2 (TLR2); and (vi) protein level of TGF-β1.

Results
Rats treated with SMY displayed the reductions of BNP and CK-MB increased by DOX in a dose-dependent manner. Moderate dose of SMY exhibited the correction for the increased HWI, LVMI, and the injured cardiac function, as well as the collagen accumulation. In addition, cardioprotection of SMY against DOX-induced cardiac toxicity was demonstrated by the reduction of myocardial fibrosis, characterized by the suppression of PICP, PШNP and TGF-β1, as well as the anti-inflammation and the regulation for cardiac immune microenvironment, characterized by the inhibition of TLR2, MCP-1, INF-γ and IL-6.

Fig1a Bar graphs showed the changes of BNP content determined via ELISA assay. SMY of both moderate dose and high dose suppressed the BNP content, with a significant reduction as compared to group DOX. b Bar graphs show the changes of CK-MB in serum. The CK-MB level was significantly inhibited by the SMY in a dose-dependent manner. Eight to ten rats in each group were analyzed in this experiment and all data were represented as mean ± standard deviation. ** P < 0.01 versus the group control, *** P < 0.001 versus the group control; #P < 0.05 versus the group DOX; ##P < 0.01 versus the group DOX

Conclusions
SMY may protect heart function through the restriction of myocardial fibrosis induced by DOX, which suggests the potentially therapeutic effect of SMY on DOX-induced cardiomyopathy.

Acknowledgments
This project was supported by the Chinese Natural Science Foundation grants 81273937.

Footnotes
Competing interests

The authors declare that they have no competing interests.

Authors’ contributions

SM, XL and YJ participated in the design of the study data analyses and manuscript preparation. LD, JZ and HZ conducted the assays and analyses. All authors read and approved the final manuscript.

References
1. De Angelis A, Piegari E, Cappetta D, Marino L, Filippelli A, Berrino L, et al. Anthracycline cardiomyopathy is mediated by depletion of the cardiac stem cell pool and is rescued by restoration of progenitor cell function. Circulation. 2010;121(2):276–292. doi: 10.1161/CIRCULATIONAHA.109.895771. [PMC free article] [PubMed] [CrossRef] [Google Scholar]
2. Minotti G, Menna P, Salvatorelli E, Cairo G, Gianni L. Anthracyclines: molecular advances and pharmacologic developments in antitumor activity and cardiotoxicity. Pharmacol Rev. 2004;56(2):185–229. doi: 10.1124/pr.56.2.6. [PubMed] [CrossRef] [Google Scholar]
3. Shuai Y, Guo JB, Peng SQ, Zhang LS, Guo J, Han G, et al. Metallothionein protects against doxorubicin-induced cardiomyopathy through inhibition of superoxide generation and related nitrosative impairment. Toxicol Lett. 2007;170(1):66–74. doi: 10.1016/j.toxlet.2007.02.010. [PubMed] [CrossRef] [Google Scholar]
4. Singal PK, Iliskovic N, Li T, Kumar D. Adriamycin cardiomyopathy: pathophysiology and prevention. FASEB J. 1997;11(12):931–936. [PubMed] [Google Scholar]
5. Singal PK, Li T, Kumar D, Danelisen I, Iliskovic N. Adriamycin-induced heart failure: mechanism and modulation. Mol Cell Biochem. 2000;207(1–2):77–86. doi: 10.1023/A:1007094214460. [PubMed] [CrossRef] [Google Scholar]
6. Swerdlow AJ, Higgins CD, Smith P, Cunningham D, Hancock BW, Horwich A, et al. Myocardial infarction mortality risk after treatment for Hodgkin disease: a collaborative British cohort study. J Natl Cancer Inst. 2007;99(3):206–214. doi: 10.1093/jnci/djk029. [PubMed] [CrossRef] [Google Scholar]
7. Das J, Ghosh J, Manna P, Sil PC. Taurine suppresses doxorubicin-triggered oxidative stress and cardiac apoptosis in rat via up-regulation of PI3-K/Akt and inhibition of p53, p38-JNK. Biochem Pharmacol. 2011;81(7):891–909. doi: 10.1016/j.bcp.2011.01.008. [PubMed] [CrossRef] [Google Scholar]
8. Ichihara S, Yamada Y, Kawai Y, Osawa T, Furuhashi K, Duan Z, et al. Roles of oxidative stress and Akt signaling in doxorubicin cardiotoxicity. Biochem Biophys Res Commun. 2007;359(1):27–33. doi: 10.1016/j.bbrc.2007.05.027. [PubMed] [CrossRef] [Google Scholar]
9. Li T, Singal PK. Adriamycin-induced early changes in myocardial antioxidant enzymes and their modulation by probucol. Circulation. 2000;102(17):2105–2110. doi: 10.1161/01.CIR.102.17.2105. [PubMed] [CrossRef] [Google Scholar]
10. Jin Z, Zhang J, Zhi H, Hong B, Zhang S, Guo H, et al. Beneficial effects of tadalafil on left ventricular dysfunction in doxorubicin-induced cardiomyopathy. J Cardiol. 2013;62(2):110–116. doi: 10.1016/j.jjcc.2013.03.018. [PubMed] [CrossRef] [Google Scholar]
11. Lam W, Bussom S, Guan F, Jiang Z, Zhang W, Gullen EA, et al. The four-herb Chinese medicine PHY906 reduces chemotherapy-induced gastrointestinal toxicity. Sci Transl Med. 2010;2(45):45ra59. doi: 10.1126/scitranslmed.3001270. [PubMed] [CrossRef] [Google Scholar]
12. Yan X, Zhang L, Guo J, Cao Y, Shang E, Tang Y, et al. Processing of kansui roots stir-baked with vinegar reduces kansui-induced hepatocyte cytotoxicity by decreasing the contents of toxic terpenoids and regulating the cell apoptosis pathway. Molecules. 2014;19(6):7237–7254. doi: 10.3390/molecules19067237. [PMC free article] [PubMed] [CrossRef] [Google Scholar]
13. Ma L, Yang L, Chen TD. Influence of large amount of shengmai injection on blood coagulation in patients with chronic heart failure. Zhongguo Zhong xi yi jie he za zhi Zhongguo Zhongxiyi jiehe zazhi = Chinese journal of integrated traditional and Western medicine / Zhongguo Zhong xi yi jie he xue hui, Zhongguo Zhong yi yan jiu yuan zhu ban. 2003;23(4):275–277. [PubMed] [Google Scholar]
14. Daowu W, Yingdong L. Protective effects of Shengmai San against myocardial damage induced by adriamycin in rats. Pharmacol Clinics Chinese Materia Medica. 1999;15(4):9–11. [Google Scholar]
15. Hai J, Limin S. Protective effects of shengmai injection on myocardium injury induced by adriamycin in rats. LiShiZhen Med Materia Medica Res. 2006;17(3):329–330. [Google Scholar]
16. Xiaodong Y, Wanqing S, Shuibing Y. Protective ef fect of Shengmai injection on adriamycin-induced myocardium injury in rats and its mechanism. Central South Pharm. 2008;6(2):162–165. [Google Scholar]
17. Zhang GQ, Wang H, Liu WT, Dong H, Fong WF, Tang LM, et al. Long-term treatment with a Chinese herbal formula, Sheng-Mai-San, improves cardiac contractile function in aged rats: the role of Ca (2+) homeostasis. Rejuvenation Res. 2008;11(6):991–1000. doi: 10.1089/rej.2008.0771. [PubMed] [CrossRef] [Google Scholar]
18. Arafa MH, Mohammad NS, Atteia HH, Abd-Elaziz HR. Protective effect of resveratrol against doxorubicin-induced cardiac toxicity and fibrosis in male experimental rats. J Physiol Biochem. 2014;70(3):701–711. doi: 10.1007/s13105-014-0339-y. [PubMed] [CrossRef] [Google Scholar]
19. Wu Z, Chen Q, Ke D, Li G, Deng W. Emodin protects against diabetic cardiomyopathy by regulating the AKT/GSK-3beta signaling pathway in the rat model. Molecules. 2014;19(9):14782–14793. doi: 10.3390/molecules190914782. [PMC free article] [PubMed] [CrossRef] [Google Scholar]
20. Lin YC, Leu S, Sun CK, Yen CH, Kao YH, Chang LT, et al. Early combined treatment with sildenafil and adipose-derived mesenchymal stem cells preserves heart function in rat dilated cardiomyopathy. J Transl Med. 2010;8:88. doi: 10.1186/1479-5876-8-88. [PMC free article] [PubMed] [CrossRef] [Google Scholar]
21. Wang J, Yuan Z, Zhao H, Ju D, Chen Y, Chen X, et al. Ferulic acid promotes endothelial cells proliferation through up-regulating cyclin D1 and VEGF. J Ethnopharmacol. 2011;137(2):992–997. doi: 10.1016/j.jep.2011.07.019. [PubMed] [CrossRef] [Google Scholar]
22. Migrino RQ, Aggarwal D, Konorev E, Brahmbhatt T, Bright M, Kalyanaraman B. Early detection of doxorubicin cardiomyopathy using two-dimensional strain echocardiography. Ultrasound Med Biol. 2008;34(2):208–214. doi: 10.1016/j.ultrasmedbio.2007.07.018. [PMC free article] [PubMed] [CrossRef] [Google Scholar]
23. Geisberg CA, Sawyer DB. Mechanisms of anthracycline cardiotoxicity and strategies to decrease cardiac damage. Curr Hypertens Rep. 2010;12(6):404–410. doi: 10.1007/s11906-010-0146-y. [PMC free article] [PubMed] [CrossRef] [Google Scholar]
24. Horenstein MS, Vander Heide RS, L'Ecuyer TJ. Molecular basis of anthracycline-induced cardiotoxicity and its prevention. Mol Genet Metab. 2000;71(1–2):436–444. doi: 10.1006/mgme.2000.3043. [PubMed] [CrossRef] [Google Scholar]
25. Psaltis PJ, Carbone A, Leong DP, Lau DH, Nelson AJ, Kuchel T, et al. Assessment of myocardial fibrosis by endoventricular electromechanical mapping in experimental nonischemic cardiomyopathy. Int J Cardiovasc Imaging. 2011;27(1):25–37. doi: 10.1007/s10554-010-9657-5. [PubMed] [CrossRef] [Google Scholar]
26. Zhou Q, Qin WZ, Liu SB, Kwong JS, Zhou J, Chen J. Shengmai (a traditional Chinese herbal medicine) for heart failure. Cochrane Database Syst Rev. 2014;4:CD005052. [PubMed] [Google Scholar]
27. Zhan S, Fan X, Zhang F, Wang Y, Kang L, Li Z. A proteomic study of Shengmai injection's mechanism on preventing cardiac ischemia-reperfusion injury via energy metabolism modulation. Mol BioSyst. 2015;11(2):540–548. doi: 10.1039/C4MB00161C. [PubMed] [CrossRef] [Google Scholar]
28. Zhang YC, Lu BJ, Zhao MH, Rong YZ, Chen RM. Effect of Shengmai injection on vascular endothelial and heart functions in patients with coronary heart disease complicated with diabetes mellitus. Chin J Integr Med. 2008;14(4):281–285. doi: 10.1007/s11655-008-0281-3. [PubMed] [CrossRef] [Google Scholar]
29. Imbaby S, Ewais M, Essawy S, Farag N. Cardioprotective effects of curcumin and nebivolol against doxorubicin-induced cardiac toxicity in rats. Hum Exp Toxicol. 2014;33(8):800–813. doi: 10.1177/0960327114527628. [PubMed] [CrossRef] [Google Scholar]
30. Swamy AV, Gulliaya S, Thippeswamy A, Koti BC, Manjula DV. Cardioprotective effect of curcumin against doxorubicin-induced myocardial toxicity in albino rats. Indian J Pharmacol. 2012;44(1):73–77. doi: 10.4103/0253-7613.91871. [PMC free article] [PubMed] [CrossRef] [Google Scholar]
31. Ertracht O, Liani E, Bachner-Hinenzon N, Bar-Am O, Frolov L, Ovcharenko E, et al. The cardioprotective efficacy of TVP1022 in a rat model of ischaemia/reperfusion. Br J Pharmacol. 2011;163(4):755–769. doi: 10.1111/j.1476-5381.2011.01274.x. [PMC free article] [PubMed] [CrossRef] [Google Scholar]
32. Haubner BJ, Neely GG, Voelkl JG, Damilano F, Kuba K, Imai Y, et al. PI3Kgamma protects from myocardial ischemia and reperfusion injury through a kinase-independent pathway. PLoS One. 2010;5(2):e9350. doi: 10.1371/journal.pone.0009350. [PMC free article] [PubMed] [CrossRef] [Google Scholar]
33. Galeotti L, Strauss DG, Ubachs JF, Pahlm O, Heiberg E. Development of an automated method for display of ischemic myocardium from simulated electrocardiograms. J Electrocardiol. 2009;42(2):204–212. doi: 10.1016/j.jelectrocard.2008.12.007. [PubMed] [CrossRef] [Google Scholar]
34. Hanninen H, Takala P, Rantonen J, Makijarvi M, Virtanen K, Nenonen J, et al. ST-T integral and T-wave amplitude in detection of exercise-induced myocardial ischemia evaluated with body surface potential mapping. J Electrocardiol. 2003;36(2):89–98. doi: 10.1054/jelc.2003.50013. [PubMed] [CrossRef] [Google Scholar]
35. Merino H, Singla DK. Notch-1 mediated cardiac protection following embryonic and induced pluripotent stem cell transplantation in doxorubicin-induced heart failure. PLoS One. 2014;9(7):e101024. doi: 10.1371/journal.pone.0101024. [PMC free article] [PubMed] [CrossRef] [Google Scholar]
36. Unverferth DV, Magorien RD, Unverferth BP, Talley RL, Balcerzak SP, Baba N. Human myocardial morphologic and functional changes in the first 24 hours after doxorubicin administration. Cancer Treatment Rep. 1981;65(11–12):1093–1097. [PubMed] [Google Scholar]
37. Yan CJ, Li SM, Xiao Q, Liu Y, Hou J, Chen AF, et al. Influence of serum adiponectin level and SNP +45 polymorphism of adiponectin gene on myocardial fibrosis. J Zhejiang Univ Sci B. 2013;14(8):721–728. doi: 10.1631/jzus.BQICC707. [PMC free article] [PubMed] [CrossRef] [Google Scholar]
38. Horslev-Petersen K, Kim KY, Pedersen LR, Bentsen KD, Uldbjerg N, Oxlund H, et al. Serum aminoterminal type III procollagen peptide. Relation to biosynthesis of collagen type III in experimentally induced granulation tissue in rats. APMIS. 1988;96(9):793–804. doi: 10.1111/j.1699-0463.1988.tb00946.x. [PubMed] [CrossRef] [Google Scholar]
39. Lin YH, Shiau YC, Yen RF, Lin LC, Wu CC, Ho YL, et al. The relation between myocardial cyclic variation of integrated backscatter and serum concentrations of procollagen propeptides in hypertensive patients. Ultrasound Med Biol. 2004;30(7):885–891. doi: 10.1016/j.ultrasmedbio.2004.04.007. [PubMed] [CrossRef] [Google Scholar]
40. Wang B, Hao J, Jones SC, Yee MS, Roth JC, Dixon IM. Decreased Smad 7 expression contributes to cardiac fibrosis in the infarcted rat heart. Am J Physiol Heart Circ Physiol. 2002;282(5):H1685–1696. doi: 10.1152/ajpheart.00266.2001. [PubMed] [CrossRef] [Google Scholar]
41. Kawano H, Do YS, Kawano Y, Starnes V, Barr M, Law RE, et al. Angiotensin II has multiple profibrotic effects in human cardiac fibroblasts. Circulation. 2000;101(10):1130–1137. doi: 10.1161/01.CIR.101.10.1130. [PubMed] [CrossRef] [Google Scholar]
42. Zhang W, Lavine KJ, Epelman S, Evans SA, Weinheimer CJ, Barger PM, et al. Necrotic myocardial cells release damage-associated molecular patterns that provoke fibroblast activation in vitro and trigger myocardial inflammation and fibrosis in vivo. J Am Heart Assoc. 2015;4(6):e001993. doi: 10.1161/JAHA.115.001993. [PMC free article] [PubMed] [CrossRef] [Google Scholar]
43. Ma Y, Zhang X, Bao H, Mi S, Cai W, Yan H, et al. Toll-like receptor (TLR) 2 and TLR4 differentially regulate doxorubicin induced cardiomyopathy in mice. PLoS One. 2012;7(7):e40763. doi: 10.1371/journal.pone.0040763. [PMC free article] [PubMed] [CrossRef] [Google Scholar]
44. Beutler B, Jiang Z, Georgel P, Crozat K, Croker B, Rutschmann S, et al. Genetic analysis of host resistance: Toll-like receptor signaling and immunity at large. Annu Rev Immunol. 2006;24:353–389. doi: 10.1146/annurev.immunol.24.021605.090552. [PubMed] [CrossRef] [Google Scholar]
Articles from BMC Complementary and Alternative Medicine are provided here courtesy of BioMed Central


People who bought this product, also bought

x
x